Day One Biopharmaceuticals Inc Forecast, price target & analysts
Day One Biopharmaceuticals Inc Target price 2025 - Analyst rating & recommendation
Day One Biopharmaceuticals Inc Classifications & Recommendation:
Day One Biopharmaceuticals Inc Price Target
| Target Price | $31.13 |
| Price | $7.71 |
| Potential |
303.70%
register free of charge
|
| Number of Estimates | 8 |
|
8 Analysts have issued a price target Day One Biopharmaceuticals Inc 2026 .
The average Day One Biopharmaceuticals Inc target price is $31.13.
This is
303.70%
register free of charge
$36.00
366.93%
register free of charge
$24.00
211.28%
register free of charge
|
|
| A rating was issued by 9 analysts: 8 Analysts recommend Day One Biopharmaceuticals Inc to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the Day One Biopharmaceuticals Inc stock has an average upside potential 2026 of
303.70%
register free of charge
|
Sales and Margin forecast 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Revenue Million $ | 131.16 | 161.73 |
| 23.31% | ||
| EBITDA Margin | -164.10% | -89.31% |
| 45.58% | ||
| Net Margin | -78.64% | -89.99% |
| 14.43% |
9 Analysts have issued a sales forecast Day One Biopharmaceuticals Inc 2025 . The average Day One Biopharmaceuticals Inc sales estimate is
This results in the following potential growth metrics:
3 Analysts have issued an Day One Biopharmaceuticals Inc EBITDA forecast 2025. The average Day One Biopharmaceuticals Inc EBITDA estimate is
This results in the following potential growth metrics and future EBITDA Margins:
9 Day One Biopharmaceuticals Inc Analysts have issued a net profit forecast 2025. The average Day One Biopharmaceuticals Inc net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029
| Dec '24 |
2025 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -1.02 | -1.44 |
| 56.96% | 41.18% | |
| P/E | negative | |
| EV/Sales | 1.56 |
9 Analysts have issued a Day One Biopharmaceuticals Inc forecast for earnings per share. The average Day One Biopharmaceuticals Inc EPS is
This results in the following potential growth metrics and future valuations:
Day One Biopharmaceuticals Inc...
Current Day One Biopharmaceuticals Inc Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 03 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Mar 25 2025 |
| JP Morgan |
Locked
➜
Locked
|
Locked | Mar 05 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Feb 26 2025 |
| Needham |
Locked
➜
Locked
|
Locked | Feb 26 2025 |
| Wedbush |
Locked
➜
Locked
|
Locked | Feb 26 2025 |
| Goldman Sachs |
Locked
➜
Locked
|
Locked | Feb 10 2025 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 03 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Mar 25 2025 |
|
Locked
JP Morgan:
Locked
➜
Locked
|
Mar 05 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Feb 26 2025 |
|
Locked
Needham:
Locked
➜
Locked
|
Feb 26 2025 |
|
Locked
Wedbush:
Locked
➜
Locked
|
Feb 26 2025 |
|
Locked
Goldman Sachs:
Locked
➜
Locked
|
Feb 10 2025 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
